Form 4: BeOne Medicines COO Sells Shares for Tax Withholding

BeOne Medicines Ltd.'s President and COO, Xiaobin Wu, sold 1,363 American Depositary Shares for $260 each to cover mandatory tax withholding related to a restricted share unit award.

Summary

• Xiaobin Wu, President and COO of BeOne Medicines Ltd. (ONC), reported a transaction on June 23, 2025.
• The transaction involved the sale of 1,363 American Depositary Shares (ADS) at a price of $260 per ADS.
• The sale was conducted to satisfy mandatory tax withholding obligations associated with the vesting of a previously granted restricted share unit (RSU) award.
• Each American Depositary Share represents 13 Ordinary Shares.
• Following the reported transaction, Mr. Wu directly beneficially owns 0 American Depositary Shares and 1,228,328 Ordinary Shares.
• Additionally, Mr. Wu indirectly beneficially owns 4,000 American Depositary Shares through his wife.
• The restricted share unit award vests at a rate of 1/4th of the securities on each anniversary of June 22, 2022, contingent upon continued service.
• Unvested securities are subject to accelerated vesting under certain termination events.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares for mandatory tax withholding upon the vesting of restricted share units, which is a neutral event from a sentiment perspective as it does not reflect a discretionary decision by the executive to sell shares.

Positives

• The transaction is a routine, non-discretionary sale for tax purposes, indicating a standard process for executive compensation rather than a negative discretionary sale.

Negatives

• The direct beneficial ownership of American Depositary Shares by the President and COO has been reduced to zero following this transaction.

Risks

• NA

Future Outlook

This SEC Form 4 filing is a disclosure of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider transaction related to executive compensation and does not provide broader industry context or trends.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary sale for tax purposes related to executive compensation, rather than a signal of management's view on the company's prospects.

Next Steps

• Continued vesting of the remaining restricted share units on each anniversary of June 22, 2022, subject to the reporting person's continued service.

Key Dates

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Trading, Executive Compensation, Restricted Share Units, Tax Withholding, American Depositary Shares, Xiaobin Wu